MedTrace Logo

Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients.

NCT07320781 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-01-08

No results posted yet for this study

Summary

This study evaluated the preemptive analgesic efficacy of Tapentadol in reducing peri operative analgesic requirements among patients undergoing breast cancer surgery.

Conditions

Interventions

DRUG

Tapentadol

75 mg oral tapentadol given 1 hour before surgery in control group and placebo tablet was given in Group B. Intraoperative and post operative morphine consumption and pain scores at 1,2,3,4 hours were calculated.

OTHER

Placebo

Placebo tablet was given in group B.

Sponsors & Collaborators

  • Shaukat Khanum Memorial Cancer Hospital & Research Centre

    lead OTHER

Principal Investigators

  • Dr. Allah Ditta Ashfaq · Shaukat Khanam Memorial Cancer Hospital & Research Centre LAHORE

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2025-09-30
Completion
2025-10-10

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07320781 on ClinicalTrials.gov